Effects of umbilical cord derived mesenchymal stem cells injection in the treatment of Spinal Muscular Atrophy (SMA)
- Conditions
- Spinal Muscular Atrophy Type 1-2 3.Spinal muscular atrophy and related syndromes
- Registration Number
- IRCT20110628006907N15
- Lead Sponsor
- Tehran University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- All
- Target Recruitment
- 60
Genetically confirmed deletion of SMN1 gene for the diagnosis of SMA disease, SMN2 gene copy number count for the diagnostic classification of disease type, Minimum age of 6 months in type I, Ventilator independent patients at the beginning of treatment in type I, Maximum age of 16 years in type II and III, Ventilator independent patients in type II and III, Absence of brain damage, Absence of liver disease, Absence of renal disease, Absence of hematological disease, Informed consent of patients and their parents
Acquired brain damage including hypoxia, ?Structural and functional brain disorders, Acute infections such as( HCV, HIV,HBV), Malignancies, Hemorrhagic diathesis, Severe anemia ( Hb less than 8 gram/dl), Renal dysfunction, Hepatic dysfunction
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method